SPAEN PRESS RELEASE:
European Commission grants marketing authorisation for Pazopanib (Votrient®) in the treatment of certain advanced soft tissue sarcoma subtypes.
[box type=»download» style=»rounded» border=»full»]Last ned pressemelding her. (pdf, 29kb)[/box]